Strides Declines to Comment on Report of Pills Unit Sale

Strides Arcolab Ltd. (STR), an Indian drugmaker, declined to comment on a report that the company may sell its unit that makes generic tablets and capsules.

“We cannot offer any comment,” Chief Financial Officer T.S. Rangan said in an interview today, adding that the company will scale up its speciality injections business. “Obviously when you have to build an injectible business, you have to defocus” on other businesses, Rangan said.

The shares rose as much as 12.4 percent and changed hands at 335.45 rupees, up 10.7 percent, at 1:11 p.m. local time.

To contact the reporter on this story: Adi Narayan in Mumbai at anarayan8@bloomberg.net

To contact the editor responsible for this story: Pradeep Kurup at pkurup3@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.